EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study

Heinz Theres, Jana Binkau, Parwis Fotuhi, Robert Flieger, Tino Schneider, Klaus-Dieter Wernecke, Gert Baumann

Heart Drug · 2001

DOI: 10.1159/000022706 ↗
AbstractBibliografische Angaben

Abstract

Background: Therapy with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers improves the prognosis of patients with impaired ventricular function, and of patients with symptoms of heart failure after acute myocardial infarction. Long-term treatment strategies for low-risk patients after acute myocardial infarction have not as yet been elucidated by clinical studies. Objective: The objective of this study is to deliver evidence of a possible additional, long-term effect from the combination of ACE inhibitors and beta-blockers, as compared with monotherapy with ACE inhibitors or beta-blockers, for patients after acute myocardial infarction but with only slightly restricted left ventricular function, and without symptoms of heart failure. Methods: In 160 patients who have suffered myocardial infarction, but do not have appreciable impairment of left ventricular ejection fraction, i.e. ejection fraction ≥40%, or symptoms of heart failure, we shall administer either monotherapy with ramipril or metoprolol, or combination therapy in the form of ramipril and metoprolol. The primary end point will be the left ventricular ejection fraction after 18 months. Secondary end points will be mortality, arrhythmia, cardiac stress tolerance, development of heart failure and the need for revascularization.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →